What is Lifesci Capital's Estimate for ATXS Q3 Earnings?

Key Points

• Analysts from Lifesci Capital forecast a Q3 2025 EPS for Astria Therapeutics at ($0.28), while the consensus for the full year is ($1.65).
• Astria Therapeutics has received multiple "buy" and "overweight" ratings from various analysts, with an average target price of $29.00.
• The company's stock is currently priced at $6.84 and has experienced a 0.5% decrease, having a market cap of approximately $385.99 million.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) - Analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for Astria Therapeutics in a note issued to investors on Wednesday, August 13th. Lifesci Capital analyst S. Slutsky expects that the biotechnology company will earn ($0.28) per share for the quarter. The consensus estimate for Astria Therapeutics' current full-year earnings is ($1.65) per share. Lifesci Capital also issued estimates for Astria Therapeutics' FY2025 earnings at ($1.81) EPS.

Several other analysts have also weighed in on the company. HC Wainwright restated a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Wednesday, August 13th. Citigroup reiterated an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. JMP Securities lifted their target price on Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Price Performance

Shares of Astria Therapeutics stock traded up $0.01 during trading on Friday, hitting $6.31. The stock had a trading volume of 199,102 shares, compared to its average volume of 358,089. The firm has a market cap of $356.14 million, a P/E ratio of -3.14 and a beta of 0.48. The business has a fifty day moving average of $6.26 and a two-hundred day moving average of $5.73. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.04.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ATXS. Fcpm Iii Services B.V. acquired a new position in Astria Therapeutics during the fourth quarter valued at $25,680,000. JPMorgan Chase & Co. raised its position in Astria Therapeutics by 4,607.1% during the second quarter. JPMorgan Chase & Co. now owns 1,696,071 shares of the biotechnology company's stock valued at $9,091,000 after buying an additional 1,660,039 shares during the period. ADAR1 Capital Management LLC raised its position in Astria Therapeutics by 605.3% during the first quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company's stock valued at $3,427,000 after buying an additional 550,706 shares during the period. Nantahala Capital Management LLC raised its position in Astria Therapeutics by 59.7% during the second quarter. Nantahala Capital Management LLC now owns 1,069,530 shares of the biotechnology company's stock valued at $5,733,000 after buying an additional 400,000 shares during the period. Finally, Vestal Point Capital LP raised its position in Astria Therapeutics by 8.2% during the second quarter. Vestal Point Capital LP now owns 4,522,000 shares of the biotechnology company's stock valued at $24,238,000 after buying an additional 342,000 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.